Standard BioTools (STU:FLB) Cyclically Adjusted Revenue per Share: €1.86 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:FLB Standard BioTools Inc STU:FLB
37 GF Score
Price €0.73
GF Value €0.45
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Standard BioTools Cyclically Adjusted Revenue per Share?

Standard BioTools STU:FLB -5.23% 37 Cyclically Adjusted Revenue per Share is €1.86 as of Mar. 2026. GuruFocus rates STU:FLB with a GF Score™ of 37/100 and a GF Value™ of €0.45 (Significantly Overvalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Standard BioTools's adjusted revenue per share for the three months ended in Mar. 2026 was €0.047. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €1.86 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Standard BioTools's average Cyclically Adjusted Revenue Growth Rate was -17.10% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -11.50% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -6.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-27), Standard BioTools's current stock price is €0.725. Standard BioTools's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €1.86. Standard BioTools's Cyclically Adjusted PS Ratio of today is 0.39.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Standard BioTools was 2.73. The lowest was 0.28. And the median was 0.75.


Standard BioTools  (STU:FLB) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Standard BioTools's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.725/1.86
=0.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Standard BioTools was 2.73. The lowest was 0.28. And the median was 0.75.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Standard BioTools Cyclically Adjusted Revenue per Share Related Terms


Standard BioTools Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Standard BioTools's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Standard BioTools Cyclically Adjusted Revenue per Share Chart

Standard BioTools Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.67 3.09 2.94 2.66 1.88

Standard BioTools Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.34 2.08 1.97 1.88 1.86

STU:FLB vs CV, ELMD, CATX: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Standard BioTools's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Standard BioTools Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Standard BioTools's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Standard BioTools's Cyclically Adjusted PS Ratio falls into.


STU:FLB
37GF Score
Standard BioTools Inc STU:FLB
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Standard BioTools Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Standard BioTools's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.047/330.2130*330.2130
=0.047

Current CPI (Mar. 2026) = 330.2130.

Standard BioTools Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.866 241.018 1.186
201609 0.680 241.428 0.930
201612 0.816 241.432 1.116
201703 0.816 243.801 1.105
201706 0.725 244.955 0.977
201709 0.602 246.819 0.805
201712 0.605 246.524 0.810
201803 0.527 249.554 0.697
201806 0.580 251.989 0.760
201809 0.633 252.439 0.828
201812 0.685 251.233 0.900
201903 0.456 254.202 0.592
201906 0.361 256.143 0.465
201909 0.346 256.759 0.445
201912 0.419 256.974 0.538
202003 0.355 258.115 0.454
202006 0.326 257.797 0.418
202009 0.467 260.280 0.592
202012 0.494 260.474 0.626
202103 0.369 264.877 0.460
202106 0.341 271.696 0.414
202109 0.318 274.310 0.383
202112 0.442 278.802 0.524
202203 0.312 287.504 0.358
202206 0.228 296.311 0.254
202209 0.328 296.808 0.365
202212 0.321 296.797 0.357
202303 0.297 301.836 0.325
202306 0.325 305.109 0.352
202309 0.300 307.789 0.322
202312 0.324 306.746 0.349
202403 0.142 312.332 0.150
202406 0.056 314.175 0.059
202409 0.054 315.301 0.057
202412 0.063 315.605 0.066
202503 0.049 319.799 0.051
202506 0.050 322.561 0.051
202509 0.044 324.800 0.045
202512 0.053 324.054 0.054
202603 0.047 330.213 0.047

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €1.86 mean?
Standard BioTools (STU:FLB) has a Cyclically Adjusted Revenue per Share of €1.86 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Standard BioTools and its competitors.
Is Standard BioTools' Cyclically Adjusted Revenue per Share too high?
Standard BioTools' current Cyclically Adjusted Revenue per Share is €1.86. Overall, Standard BioTools has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Standard BioTools' Cyclically Adjusted Revenue per Share compare to CV and ELMD?
Standard BioTools' Cyclically Adjusted Revenue per Share of €1.86 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Standard BioTools and its competitors. Standard BioTools's current Cyclically Adjusted Revenue per Share is €1.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Standard BioTools stock overvalued right now?
Based on GuruFocus' analysis, Standard BioTools (STU:FLB) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.45, compared to a current price of €0.73 — trading 61.1% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is €1.86. Standard BioTools' overall GF Score™ is 37/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Standard BioTools (STU:FLB), the current Cyclically Adjusted Revenue per Share is €1.86 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Standard BioTools (STU:FLB) Overvalued in 2026?

Based on GuruFocus' analysis, Standard BioTools stock appears to be overvalued. The current stock price of €0.73 is trading 61.1% above its estimated GF Value™ of €0.45. GuruFocus considers Standard BioTools to be Significantly Overvalued.

Key valuation signals for STU:FLB:

  • Cyclically Adjusted Revenue per Share: €1.86
  • GF Value™: €0.45 vs. price of €0.73 (61.1% above fair value)
  • GF Score™: 37/100 with 5 warning signs

No single metric tells the full story. See the STU:FLB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Standard BioTools Business Description

Other Exchanges LAB:USA
Address 50 Milk Street, 10th Floor, Boston, MA, USA, 02109
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.
37GF Score

Get the complete analysis for STU:FLB

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.73
Price
€0.45
GF Value